2018 was the year CBD was on everyone’s lips, thanks to plenty of media buzz and the suddenly-ubiquitous presence of an array of CBD-infused beverages, lotions and self-care products. It was also the year “CBD gummies” reached No. 3 on Google’s most popular search terms. And I’m willing to go out on a limb that a significant portion of those searches were made by Baby Boomers.

Cannabidiol (CBD), a non-intoxicating compound found in cannabis, is being touted as a natural remedy for chronic pain, insomnia, depression and anxiety, among other conditions. The research to prove CBD’s therapeutic outcomes is still largely forthcoming. But even without the science, it’s no wonder that adults over 50, who suffer most from these conditions, are behind one of the fastest growing market segments for CBD products.


In a historic reconsideration of cannabis’ Schedule 1 classification, the FDA proved willing to acknowledge that a component of cannabis actually does have therapeutic value. Riding the coattails of GW Pharmaceuticals’ Epidiolex, the first cannabis-based drug to receive FDA approval, CBD was rescued from Schedule 1 exile, joining cough syrup and anti-diarrhea remedies in the comfortable Schedule 5 mainstream.

Late 2018 also saw passage of the Farm Bill, which could ultimately guarantee a steady, domestic supply of CBD sourced from hemp. Like the FDA, Congress acknowledged that not all cannabis compounds are equal, and removed hemp (cannabis sativa with THC levels under 0.3{6869a04b09101587efe6b502a1ddd9476710fdb033e3dfcb32726f46272f1018}) from the restrictions of the Controlled Substance Act.